, Volume 29, Issue 11, pp 336-341
Date: 20 Sep 2013

Buprenorphine/naloxone sublingual tablet (Zubsolv®): a guide to its use in the maintenance treatment of opioid dependence in the USA

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Zubsolv® is a new sublingual formulation of buprenorphine/naloxone that is indicated for the maintenance treatment of opioid dependence in the USA. The effectiveness and tolerability of buprenorphine/naloxone in this indication is well established. Relative to other sublingual formulations of buprenorphine/naloxone, Zubsolv® dissolves more rapidly, has greater bioavailability, tastes better, and may be preferred by many patients.